Nestle is reportedly cutting ties with Indonesia's Astra Agro Lestari over land rights and environmental abuses.
Volkswagen Korea’s dealers was said to be promising customers that they can immediately receive their cars regardless of waiting number.
The long-term nature of Arsenl's extension means there’s a real commitment to collaborate with Adidas.
South Korea’s state power utility decided to jack up the adjusted unit fuel cost by 2.5 won per kilowatt hour.
Korean Air's merger with Asiana Airlines is expected to get approval from the US and UK in November.
MLP will have 16 teams instead of 12 in 2023, and players will compete in six events spread over six cities for more than US$2 million.
The beverage firm will leverage its deals with the Uefa Champions League clubs to launch new marketing campaigns.
Breweries are concerned that demand will plummet from October when consumers become even more budget-minded.
ondon Heathrow maintained its first-place ranking among European hubs, but it dropped from its global ranking of number 1 in 2019 to number 22 this year.
Samuel’s endorsement deal with the Jordan brand comes after he signed a three-year, US$73.5 million contract extension ahead of the 2022 season.
The bond’s net proceeds will go to projects that meet the eligibility criteria outlined in the group’s Green Finance Framework.
Korean Air will receive SAF from Shell at major airports in the Asia-Pacific and the Middle East regions.
Samsung Biologics, C&T announce $15M investment in Senda Biosciences
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
What is a semiconductor? An electrical engineer explains how these critical electronic components work and how they are made